Business / Finance

RSS

Lantheus commences solicitation with respect to 9.750% Senior Notes Due 2017

Lantheus Medical Imaging, Inc. today announced it commenced a consent solicitation with respect to a proposed amendment to the indenture governing the company's outstanding 9.750% Senior Notes Due 2017.

5 Mar 2011

Major providers of prison medical care set to merge

Valitas Health Services plans to acquire America Service Group for $250 million, merging two of the largest providers of correctional health care. Valitas, of St. Louis, is the parent company of Correctional Medical Services.

5 Mar 2011

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2010.

5 Mar 2011

ThermoGenesis prices offering of 2,250,000 shares of common stock

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that it has determined the pricing for an offering of shares and warrants.

4 Mar 2011

Prism Medical revenues in fiscal 2010 is $66.6 million

Prism Medical Ltd. today announced its results for the fiscal year ended November 30, 2010. Revenues in fiscal 2010 were $66.6 million compared to $65.7 million in fiscal 2009.

4 Mar 2011

Amgen acquires BioVex Group

Harris & Harris Group, Inc. notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc.

4 Mar 2011

CBAI modifies authorized shares from pro-rata 500 to 250 million

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that the Company's management team and board of directors has modified the proposed one share for each 500 outstanding shares reverse stock split to one share for each 100 outstanding shares.

4 Mar 2011

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

Corporations brace for health law gains and losses

Two corporations offer very different views of how changes resulting from the health overhaul will impact their bottom lines.

3 Mar 2011

International Surf Resorts to acquire BioZone Laboratories

International Surf Resorts, Inc., to be renamed BioZone Pharmaceuticals, Inc., today announced a binding option and letter of intent with BioZone Laboratories, Inc. and related companies.

2 Mar 2011

Cyberonics third quarter net sales increase 15.3% to $47.1 million

Cyberonics, Inc., a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.

2 Mar 2011

Reliv fourth-quarter net sales decrease to $18.5 million

Reliv International, Inc. a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth-quarter and full-year of 2010.

2 Mar 2011

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2010.

2 Mar 2011

Mylan confirms lawsuit relating to Estradiol Transdermal System ANDA

Mylan Inc. today confirmed that the company has been sued by Vivelle Ventures LLC, Noven Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Estradiol Transdermal System, USP (Twice-Weekly), 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day.

2 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Thermo Fisher Scientific plans for new manufacturing facility in China

Thermo Fisher Scientific Inc., the world leader in serving science, today announced plans for a new manufacturing facility in China within the Suzhou Science and Technology Town - part of the company's strategy to aggressively expand its presence in the Asia-Pacific region.

From Thermo Fisher Scientific Inc. 2 Mar 2011

GenMark announces dismissal of microfluidic technology patent lawsuit against Caliper Life Sciences

GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.

2 Mar 2011

Advion to establish new laboratory at Purdue Research Park near Indianapolis

Advion BioServices Inc., a provider of contract bioanalytical research services, announced that it will establish a laboratory here, creating 49 immediate jobs and up to 66 jobs by 2015.

From Advion 2 Mar 2011

Market demands shape health sector growth

The Wall Street Journal reports on how a string of recent acquisitions are being spurred by an increased demand for outpatient facilities and senior care. However, The Washington Post reports that some specific facilities — those that are doctor-owned, for instance — are sparking criticism.

1 Mar 2011

Pfizer acquires King Pharmaceuticals

Pfizer Inc. today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary of Pfizer.

1 Mar 2011